News From Sentrimed
Sentrimed is an emerging biotech company developing novel, targeted therapies that exploit cell-to-cell communications essential to recognizing, immobilizing and eliminating abnormal cells. Our company is focused on:
INNOVATION
Unique, IP protected assets targeting novel validated pathways critical to cancer progression
PATIENT-CENTRICITY
Biomarker driven, well-tolerated, oral medications focused on aggressive cancers with significant unmet needs
ENDURING IMPACT
Immobilize and eliminate tumor cells throughout the care continuum, alone or in combination with other agents